Concord Biotech Ltd.

₹2071.0

Concord Biotech Ltd.

₹2071.0

₹2071.0

-24.8 (-1.18%) - 17 Jun 2025 04:22 PM

About Company

Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including regulated markets, such as the United States, Europe and Japan and India. It commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. In 2016, it launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.

Market Cap. ₹ 21,925 Cr.
52 Week - High/Low ₹ 2,664/1,345
P/E Ratio 58.79
P/B Ratio 14.37
Enterprise Value ₹ 21,962 Cr.
ROE % 21.63
RSI Value -
EMA 50 1753.75
EMA 200 1773.19
Market Cap. ₹ 21,925 Cr.
52 Week - High/Low ₹ 2,664/1,345
P/E Ratio 58.99
P/B Ratio 14.36
Enterprise Value ₹ 21,962 Cr.
ROE % 21.88
RSI Value -
EMA 50 1753.75
EMA 200 1773.19

Growth

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.